468 related articles for article (PubMed ID: 27526553)
1. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A
Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
[TBL] [Abstract][Full Text] [Related]
2. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
Pascale A; Serfaty L
J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
[TBL] [Abstract][Full Text] [Related]
3. First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients.
Chachá SGF; Rodrigues JPV; Araújo RC; Pereira LRL; Villanova MG; Souza FF; Santana RC; Martinelli ALC
Rev Soc Bras Med Trop; 2018; 51(2):146-154. PubMed ID: 29768546
[TBL] [Abstract][Full Text] [Related]
4. Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan.
Hsieh MH; Yeh ML; Su TH; Liu TW; Huang CF; Huang CI; Wang SC; Huang JF; Dai CY; Kao JH; Chuang WL; Chen PJ; Liu CJ; Yu ML
J Formos Med Assoc; 2018 Jun; 117(6):497-504. PubMed ID: 28694000
[TBL] [Abstract][Full Text] [Related]
5. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
[TBL] [Abstract][Full Text] [Related]
6. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
Ferenci P; Reddy KR
Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
[TBL] [Abstract][Full Text] [Related]
7. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
8. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
9. Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort.
Mauss S; Böker K; Buggisch P; Christensen S; Hofmann WP; Schott E; Pfeiffer-Vornkahl H; Alshuth U; Hüppe D
Z Gastroenterol; 2015 Jul; 53(7):644-54. PubMed ID: 26167694
[TBL] [Abstract][Full Text] [Related]
10. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
Poizot-Martin I; Bellissant E; Garraffo R; Colson P; Piroth L; Solas C; Renault A; Bourlière M; Halfon P; Ghosn J; Alric L; Naqvi A; Carrieri P; Molina JM;
HIV Clin Trials; 2016 Mar; 17(2):63-71. PubMed ID: 27077673
[TBL] [Abstract][Full Text] [Related]
11. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
Jacobson IM; Marcellin P; Zeuzem S; Sulkowski MS; Esteban R; Poordad F; Bruno S; Burroughs MH; Pedicone LD; Boparai N; Deng W; DiNubile MJ; Gottesdiener KM; Brass CA; Albrecht JK; Bronowicki JP
Hepatology; 2012 Aug; 56(2):567-75. PubMed ID: 22619063
[TBL] [Abstract][Full Text] [Related]
12. Boceprevir: a protease inhibitor for the treatment of hepatitis C.
Chang MH; Gordon LA; Fung HB
Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763
[TBL] [Abstract][Full Text] [Related]
13. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
Vierling JM; Davis M; Flamm S; Gordon SC; Lawitz E; Yoshida EM; Galati J; Luketic V; McCone J; Jacobson I; Marcellin P; Muir AJ; Poordad F; Pedicone LD; Albrecht J; Brass C; Howe AY; Colvard LY; Helmond FA; Deng W; Treitel M; Wahl J; Bronowicki JP
J Hepatol; 2014 Apr; 60(4):748-56. PubMed ID: 24362076
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
Calleja JL; Pascasio JM; Ruiz-Antorán B; Gea F; Bárcena R; Larrubia JR; Pérez-Álvarez R; Sousa JM; Romero-Gómez M; Solá R; de la Revilla J; Crespo J; Navarro JM; Arenas JI; Delgado M; Fernández-Rodríguez CM; Planas R; Buti M; Forns X;
Liver Int; 2015 Jan; 35(1):90-100. PubMed ID: 25113158
[TBL] [Abstract][Full Text] [Related]
15. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
[TBL] [Abstract][Full Text] [Related]
16. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
[TBL] [Abstract][Full Text] [Related]
17. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
Lim KB; Sima HR; Fiel MI; Khaitova V; Doucette JT; Chernyiak M; Ahmad J; Bach N; Chang C; Grewal P; Kim-Schluger L; Liu L; Odin J; Perumalswami P; Florman SS; Schiano TD
World J Gastroenterol; 2015 May; 21(20):6236-45. PubMed ID: 26034358
[TBL] [Abstract][Full Text] [Related]
18. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
19. Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects.
Lawitz EJ; Membreno FE
J Gastroenterol Hepatol; 2014 Aug; 29(8):1574-81. PubMed ID: 24852401
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
Bruno S; Vierling JM; Esteban R; Nyberg LM; Tanno H; Goodman Z; Poordad F; Bacon B; Gottesdiener K; Pedicone LD; Albrecht JK; Brass CA; Thompson S; Burroughs MH
J Hepatol; 2013 Mar; 58(3):479-87. PubMed ID: 23183529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
